OrthoTrophix Will Present Clinical Outcome of a TPX-100 Study Including Knee Cartilage Structure Modification Data at Annual Meeting of American College of Rheumatology 2018


OAKLAND, Calif.,  /PRNewswire/ -- OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company and its collaborators will present a late breaking abstract entitled, "Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months is Associated with Increased Tibiofemoral Cartilage Thickness" at American College of Rheumatology (ACR/ARHP) Annual Meeting in Chicago, IL.

Our drug has demonstrated to improve and sustain knee function in knee osteoarthritis patients for a long time. (PRNewsFoto/OrthoTrophix, Inc.) (PRNewsfoto/OrthoTrophix, Inc.)

Abstract number L16 will be presented at the Late Breaking Abstract Session by Dawn McGuire, M.D., the company's Chief Medical Officer at a podium presentation at 4:20pm on Tuesday, October 23rd, 2018.

About OrthoTrophix, Inc.

OrthoTrophix, Inc., based in Oakland, California, is a privately held biopharmaceutical company focused on the development and commercialization of revolutionary therapeutics for the treatment of diseases and conditions involving the hard tissues.  Founded by three co-founders in 2011, the primary focus of OrthoTrophix has been regeneration and repair of cartilage in the knee and other joints with its novel proprietary compounds which promote formation of new cartilage and bone tissues and thereby repair the respective defects.  OrthoTrophix has received over $30 million from its preferred stock financing and research and development revenues since its inception.

This press release contains "forward-looking" statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. OrthoTrophix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect OrthoTrophix' business.

Company Contact
Yoshi Kumagai
President and CEO
Tel:  (510) 488-3824



Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/orthotrophix-will-present-clinical-outcome-of-a-tpx-100-study-including-knee-cartilage-structure-modification-data-at-annual-meeting-of-american-college-of-rheumatology-2018-300729060.html

SOURCE OrthoTrophix, Inc.


Back to news